These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 17216435)

  • 41. Mefloquine pharmacokinetics in healthy subjects and in peptic ulcer patients after cimetidine administration.
    Kolawole JA; Mustapha A; Abudu-Aguye I; Ochekpe N
    Eur J Drug Metab Pharmacokinet; 2000; 25(3-4):165-70. PubMed ID: 11420885
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Population pharmacokinetics of enterally administered cisapride in young infants with gastro-oesophageal reflux disease.
    Preechagoon Y; Charles B; Piotrovskij V; Donovan T; Van Peer A
    Br J Clin Pharmacol; 1999 Nov; 48(5):688-93. PubMed ID: 10594470
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prevalence of contraindications to mefloquine use among USA military personnel deployed to Afghanistan.
    Nevin RL; Pietrusiak PP; Caci JB
    Malar J; 2008 Feb; 7():30. PubMed ID: 18267019
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Population pharmacokinetics of oral baclofen at steady-state in alcoholic-dependent adult patients.
    Chevillard L; Sabo N; Tod M; Labat L; Chasport C; Chevaleyre C; Thibaut F; Barré J; Azuar J; Questel F; Vorspan F; Bloch V; Bellivier F; Granger B; Barrault C; Declèves X
    Fundam Clin Pharmacol; 2018 Apr; 32(2):239-248. PubMed ID: 29091319
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Population pharmacokinetics of onercept in healthy subjects.
    Glatt S; Fuseau E; Buraglio M; Nguyen QT
    Clin Pharmacokinet; 2005; 44(12):1295-304. PubMed ID: 16372827
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The influence of body weight on the pharmacokinetics of mefloquine.
    SImpson JA; Aarons L; Price R; White NJ
    Br J Clin Pharmacol; 2002 Mar; 53(3):337-8. PubMed ID: 11874399
    [No Abstract]   [Full Text] [Related]  

  • 47. Stereoselective pharmacokinetics of mefloquine in healthy Caucasians after multiple doses.
    Gimenez F; Pennie RA; Koren G; Crevoisier C; Wainer IW; Farinotti R
    J Pharm Sci; 1994 Jun; 83(6):824-7. PubMed ID: 9120814
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Gender-specific distribution of mefloquine in the blood following the administration of therapeutic doses.
    Wernsdorfer WH; Noedl H; Rendi-Wagner P; Kollaritsch H; Wiedermann G; Mikolasek A; Karbwang J; Na-Bangchang K
    Malar J; 2013 Dec; 12():443. PubMed ID: 24321055
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Tafenoquine for malaria prophylaxis in adults: An integrated safety analysis.
    Novitt-Moreno A; Ransom J; Dow G; Smith B; Read LT; Toovey S
    Travel Med Infect Dis; 2017; 17():19-27. PubMed ID: 28495354
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Coadministration of mefloquine and chloroqine: use of a pharmacokinetic-based approach to reduce toxicity.
    Lowry JA; Corry A; Fitzmaurice L; Jackson MA; Kearns GL
    Pediatr Infect Dis J; 2001 Feb; 20(2):223-4. PubMed ID: 11224849
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Mefloquine prophylaxis.
    Arthur JD; Shanks GD; Echeverria P
    Lancet; 1990 Apr; 335(8695):972. PubMed ID: 1970042
    [No Abstract]   [Full Text] [Related]  

  • 52. A Population Pharmacokinetic Analysis of Dextroamphetamine in the Plasma and Hair of Healthy Adults.
    Roberts JK; Cook SF; Stockmann C; Rollins DE; Wilkins DG; Sherwin CM
    Clin Drug Investig; 2015 Oct; 35(10):633-43. PubMed ID: 26329917
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Population pharmacokinetic modelling of febuxostat in healthy subjects and people with gout.
    Kamel B; Abuhelwa AY; Foster D; Duong JK; Graham GG; Williams KM; Pile KD; Day RO
    Br J Clin Pharmacol; 2022 Dec; 88(12):5359-5368. PubMed ID: 35849446
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Population pharmacokinetics of rectal theophylline in neonates.
    Karlsson MO; Thomson AH; McGovern EM; Chow P; Evans TJ; Kelman AW
    Ther Drug Monit; 1991 May; 13(3):195-200. PubMed ID: 1926271
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Population pharmacokinetics of perhexiline from very sparse, routine monitoring data.
    Hussein R; Charles BG; Morris RG; Rasiah RL
    Ther Drug Monit; 2001 Dec; 23(6):636-43. PubMed ID: 11802096
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Neurological, cardiovascular and metabolic effects of mefloquine in healthy volunteers: a double-blind, placebo-controlled trial.
    Davis TM; Dembo LG; Kaye-Eddie SA; Hewitt BJ; Hislop RG; Batty KT
    Br J Clin Pharmacol; 1996 Oct; 42(4):415-21. PubMed ID: 8904612
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Influence of hemodialysis on plasma concentration-time profiles of mefloquine in two patients with end-stage renal disease: a prophylactic drug monitoring study.
    Crevoisier CA; Joseph I; Fischer M; Graf H
    Antimicrob Agents Chemother; 1995 Aug; 39(8):1892-5. PubMed ID: 7486943
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Population pharmacokinetics of telapristone (CDB-4124) and its active monodemethylated metabolite CDB-4453, with a mixture model for total clearance.
    Morris D; Podolski J; Kirsch A; Wiehle R; Fleckenstein L
    AAPS J; 2011 Dec; 13(4):665-73. PubMed ID: 22028249
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effect of tetracycline on mefloquine pharmacokinetics in Thai males.
    Karbwang J; Na Bangchang K; Back DJ; Bunnag D; Rooney W
    Eur J Clin Pharmacol; 1992; 43(5):567-9. PubMed ID: 1483498
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Population Pharmacokinetic Model for Tramadol and O-desmethyltramadol in Older Patients.
    Al-Qurain AA; Upton RN; Tadros R; Roberts MS; Wiese MD
    Eur J Drug Metab Pharmacokinet; 2022 May; 47(3):387-402. PubMed ID: 35167052
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.